Byondis

Our CEO Christoph Korpus joined the Leaders in Life Sciences Podcast discussing how Byondis is engineering antibody-drug conjugates (ADCs) to tackle cancers that current therapies cannot reach. Listen to the full episode here: leadersinlifesciences.nl/afl… #Byondis #ADC

Next week, our Senior Director of Business Development and Licensing, Ivo Grgic, will be at #BIOEurope in Cologne. If you are also attending and would like to connect, reach out to [email protected]. #ADCs #Partnering

Join our CEO, Christoph Korpus, will be joining a panel discussion at BioTech Connect to share his perspective on the European funding ecosystem and what it takes to scale globally from Europe. Reserve your ticket here: hollandbio.nl/en/event-en/bi… #Partnerships #Byondis #BioPitch

#ICYMI our CEO Christoph Korpus joined ICR Healthcare’s latest Conference Series webinar on next-generation #ADC innovation, discussing how Byondis’ platforms are designed to overcome resistance and off-tumor toxicity. Watch the replay here: linkedin.com/safety/go/?url=…

Our CSO Wim Dokter, PhD will present at #WorldADC San Diego next week, showcasing the potential of our ADC platform technologies. Read more: byondis.com/investors-and-me…

Our CEO, Christoph Korpus, joins the ICR Healthcare Conference Series on evolving ADCs beyond current payload and toxicity limits, alongside leaders from VERAXA, Adcytherix, and Callio. Register here: icr.swoogo.com/adc/begin #ADCs #Byondis

Join our CEO, Christoph Korpus, at @BioCentury Grand Rounds: Europe in Amsterdam, where he will be giving a presentation on Byondis’ novel #ADC platforms as part of the Oncology track. If you are attending and would like to connect, please reach out to [email protected].

Meet Ivo Ggric and Steven Bartz at #BIOInternational next week and learn more about our novel platforms & technologies evolving the #ADC field. Reach out to [email protected] #Byondis

We are excited to announce that Steven Bartz, Ph.D., will be joining Byondis as our Strategic BD&L Advisor, bringing over 20 years of biopharma leadership with deep expertise in advancing innovative therapeutics and technology platforms. Welcome Steven! #Byondis

We are proud to announce the formation of our Scientific Advisory Board, bringing together internationally recognized experts in antibody-drug conjugate (#ADC) science, therapeutic antibody engineering, and oncology clinical development: globenewswire.com/news-relea… #Byondis

#AACR2026 takeaway: ADCs need real differentiation — novel mechanisms, better selectivity, and smarter approaches to resistance. That is what we're building with our platform technologies designed to expand what targeted cancer medicines can do.

Next week our Senior Director Business Development Ivo Grgic will be heading to Swiss Biotech Day. If you are also attending and would like to connect, reach out to [email protected]. #ADCs #SwissBiotechDay

Next week, our CEO, Christoph Korpus, will be heading to Prague to present at #BioEquityEurope 2026. If you are also attending and would like to connect, reach out to [email protected] or via the partneringONE™ platform. #ADCs #Partnering #BioEquity2026

Our Project Leader Mary van Helden discusses Byondis' innovative immunostimulatory phosphonate ADCs with Lauren Coyle, @Bio_Insights. Learn more about the interview here: insights.bio/bioconjugate-in… #Innovation #AntibodyDrugConjugates

Join our Chief Science Officer @Wim Dokter at the @AACR Annual Meeting as he presents two posters showcasing Byondis’ technology. Reach out if you would like to meet the #Byondis team: [email protected] #Innovation #AntibodyDrugConjugates

Our CEO Christoph Korpus is heading to the @AACR #Oncology Industry Partnering Event in San Diego this week, ahead of the #AACR Annual Meeting. Reach out if you’ll be there and would like to meet the #Byondis team: [email protected] #Innovation #AntibodyDrugConjugates

Today we announce the #appointment of Dr. Christoph Korpus as our new CEO. In his new role, he will guide the advancement of our proprietary #ADC platforms as we work to deliver breakthrough solutions for people living with cancer. Read more: businesswire.com/news/home/2…

Two abstracts highlighting the science behind our innovative ADC technology platforms have been selected as poster presentations at the American Association for Cancer Research Meeting. #AACR26 #AntibodyDrugConjugates #ADCs #OncologyResearch #Oncology #Byondis #MakeHopeReal

Byondis will be at #BioEuropeSpring! Please reach out if you are interested in meeting with Ivo and our team to discuss strategic collaborations, licensing opportunities, and other partnership possibilities: [email protected]. #BIOEurope #ADCInnovation #AntibodyDrugConjugates #ADCs

📣 Bas Kokke, PhD, Principal Scientist of Downstream Processing, will be presenting at the BioProcessing Summit 2026 on "Viral Clearance and Removal of Host-Cell Proteins" an important contribution to the development of innovative compounds like Byondis' work with (masked) ADCs.